Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Britain Courts Anthropic Amid US Defense Department Dispute 
Apple Turns 50: From Garage Startup to AI Crossroads 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
PHOENIX, Dec. 08, 2016 -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today issued the following statement regarding the Department of Justice / U.S. Attorney’s Office / District of Massachusetts press release:
The charges against individuals discussed in the DOJ press release relate to previously disclosed investigations. Insys continues to cooperate with all relevant authorities in its ongoing investigations and is committed to complying with laws and regulations that govern our products and business practices. Insys will not provide additional information or comments at this time on this matter.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients.
Investor Contact: Lisa M. Wilson Email: [email protected]
